

Date: July 11, 2023

То	То
The Listing Department	The Listing Department
National Stock Exchange of India Limited	Bombay Stock Exchange Limited
Exchange Plaza,	Floor 25, P. J. Towers,
Bandra – Kurla Complex	Dalal Street,
Bandra (East)	<u>Mumbai – 400 001</u>
<u>Mumbai – 400 051</u>	Stock Code : 532612
Stock Code : INDOCO-EQ	

Dear Sir/Madam,

<u>Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)</u> <u>Regulations, 2015 – Completion of Inspection at Indoco Remedies Limited Goa Plant-III</u>

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that German Health Authority (LAGeSo) had inspected Company's manufacturing facility (Plant III) located at Goa ("Facility") for oral dosage form, from April 20, 2023 to April 25, 2023.

The Facility has received EU GMP certification from Competent Health Authority of Germany (LAGeSo) confirming that Facility complies with the Good Manufacturing Practice requirements as referred in the EC Directive.

Please find enclosed herewith press release in this regard. Kindly take the above information on record.

Thanking you, Yours faithfully, For Indoco Remedies Limited



Ramanathan Hariharan Company Secretary & Head- Legal





PRESS RELEASE

Indoco's Goa facility (Plant III) receives EU GMP certification from the German Health Authority

Mumbai, July 11, 2023: Indoco Remedies received EU GMP certification from the Competent Health Authority of Germany for its manufacturing site situated at L-32/33/34 Verna Industrial Estate, Goa. The European Agency conducted an inspection at Indoco's manufacturing facility for solid oral dosage form in Goa (Plant -III) from April 20-25, 2023.

The EU GMP certification issued by the German Health Authority (LAGeSo) confirms that the site complies with the Good Manufacturing Practice requirements as referred to in the EC Directive. The EU certification will support supplies of drug products registered in Europe and other regions from this manufacturing site.

Commenting on the development, **Ms. Aditi Panandikar, Managing Director – Indoco Remedies Ltd.** said, "The EU GMP certification for our site in Goa (Plant - III) complements our unswerving efforts to supply quality and affordable medicines in Europe and other geographies. We remain fully committed to adhering to cGMP standards and ensuring the delivery of quality products to our valued customers and patients worldwide."

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries. The Company's turnover is US\$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field Staff who are the strength of the organization.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit <u>www.indoco.com</u>

For Media Inquiries, please contact: Pramod Ghorpade Mobile: 9619883225 E-mail: pramod.ghorpade@indoco.com / corpcom@indoco.com